CARDIOVASCULAR JOURNAL OF AFRICA • Vol 22, No 2, March/April 2011
84
AFRICA
Report of the Joint National Committee on Prevention, Detection,
Evaluation, and Treatment of High Blood Pressure.
Hypertension
2003;
42
: 1206–1252.
12. Lewington S, Clarke R, Qizilbash N,
et al
. Age-specific relevance of
usual blood pressure to vascular mortality: a meta-analysis of individual
data for one million adults in 61 prospective studies.
Lancet
2002;
360
:
1903–1913.
13. WHO. Obesity: Preventing and managing the Global Epidemic – Report
of a WHO Consultation on Obesity, 3–5 June 1997, Geneva (Last
assessed on 3 March 2010).
/
obesity_executive_summary.pdf
14. Opie LH, Mayosi BM. Cardiovascular disease in sub-Saharan Africa.
Circulation
2005;
112
: 3536−3540.
15. Exner DV, Dries DL, Domanski MJ, Cohn JN. Lesser response to
angiotensin-converting-enzyme inhibitor therapy in black as compared
with white patients with left ventricular dysfunction.
N Engl J Med
2001;
344
:1351–1357.
16. Rahman M, Douglas JG, Wright JT. Pathophysiology and treatment
implications of hypertension in the African-American population.
Endocrinol Metab Clin North Am
1997;
26
: 125–144.
17. Sareli P, Radevski IV, Valtchanova ZP,
et al
. Efficacy of different drug
classes used to initiate antihypertensive treatment in black subjects.
Results of a randomized trial in Johannesburg, South Africa.
Arch Intern
Med
2001;
161
: 965–971.
18. Wright JT, Jr, Bakris G; Greene T,
et al.
Effect of blood pressure lower-
ing and antihypertensive drug class on progression of hypertensive
kidney disease results from the AASK trial.
J Am Med Assoc
2002;
288
:
2421–2431.
19. Yusuf S, Sleight P, Pogue J,
et al
. Effects of an angiotensin-convert-
ing-enzyme inhibitor, ramipril, on cardiovascular events in high-risk
patients. The Heart Outcomes Prevention Evaluation study investigators.
N Engl J Med
2000;
342
: 145–153.
20. The Acute Infarction Ramipril Efficacy (AIRE) study investigators.
Effect of ramipril on mortality and morbidity of survivors of acute
myocardial infarction with clinical evidence of heart failure.
Lancet
1993;
342
: 821–828.
21. Kostis JB, Kim HJ, Rusnak J,
et al
. Incidence and characteristics of
angioedema associated with enalapril.
Arch Intern Med
2005;
165
:
1637–1642.
22. Cupido C, Rayner B. Life-threatening angio-oedema and death associ-
ated with the ACE inhibitor Enalapril.
S Afr Med J
2007;
97
: 244–245.
23. Seedat YK, Croasdale MA, Milne FJ,
et al
. Guideline committee,
Southern African Hypertension Society. South African hypertension
guideline 2006.
S Afr Med J
2006;
96
: 337–362
24. ALLHAT collaborative research group. Diuretic versus
α
-blocker as first-
step antihypertensive therapy. Final results from the Antihypertensive
and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT).
Hypertension
2003;
42
: 239–246.
This peer-reviewed journal is available as full text at all tertiary institutions in
South Africa, presenting a great opportunity to submit your
good-quality original articles for speedy publication.
Recent user research has shown that some 10 000 annual topic searches
were done on the
SA Journal of Diabetes & Vascular Disease
database,
which contains seven years of published material.
The
SA Journal of Diabetes & Vascular Disease
aims to provide a forum for specialists
involved in the care of people with diabetes, to exchange information, promote better
management and stimulate research in Africa.
This quarterly journal publishes original research and scholarly reviews about preven-
tion and management of diabetes, relating to both general and specific issues.
The
SA Journal of Diabetes & Vascular Disease
invites you to submit
your articles online only. Read the Instructions to Authors at
for more information on the journal’s policies and the submission process.
Call for
Articles
